

# Fujie Zhang

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/663560/publications.pdf](https://exaly.com/author-pdf/663560/publications.pdf)

Version: 2024-02-01

121  
papers

4,229  
citations

132755

30  
h-index

117790

58  
g-index

134  
all docs

134  
docs citations

134  
times ranked

6210  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. <i>Clinical Infectious Diseases</i> , 2020, 71, 793-798.	5.6	593
2	Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 516-524.	8.7	234
3	Five-Year Outcomes of the China National Free Antiretroviral Treatment Program. <i>Annals of Internal Medicine</i> , 2009, 151, 241.	10.0	223
4	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	13.8	207
5	The Chinese free antiretroviral treatment program: challenges and responses. <i>Aids</i> , 2007, 21, S143-S148.	2.1	161
6	A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19. <i>Nature Metabolism</i> , 2021, 3, 909-922.	11.1	155
7	Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-2011): a national observational cohort study. <i>Lancet</i> , The, 2013, 382, 1195-1203.	11.9	129
8	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 253-264.	8.7	129
9	HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-2012: a retrospective observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1065-1072.	8.7	111
10	The Effect of Highly Active Antiretroviral Therapy on Mortality among HIV-Infected Former Plasma Donors in China. <i>Clinical Infectious Diseases</i> , 2008, 47, 825-833.	5.6	91
11	CD14 <sup>high</sup> CD16 <sup>+</sup> Rather Than CD14 <sup>low</sup> CD16 <sup>+</sup> Monocytes Correlate With Disease Progression in Chronic HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 553-559.	2.1	82
12	On-surface lithium donor reaction enables decarbonated lithium garnets and compatible interfaces within cathodes. <i>Nature Communications</i> , 2020, 11, 5519.	12.8	78
13	Predictors of Virologic Failure in HIV-Infected Adults Receiving First-Line Antiretroviral Therapy in 8 Provinces in China. <i>Clinical Infectious Diseases</i> , 2010, 50, 264-271.	5.6	74
14	Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. <i>Journal of Infection</i> , 2020, 81, e26-e30.	3.3	74
15	Cohort Profile: The Chinese national free antiretroviral treatment cohort. <i>International Journal of Epidemiology</i> , 2010, 39, 973-979.	2.0	68
16	HIV-Infected Former Plasma Donors in Rural Central China: From Infection to Survival Outcomes, 1985-2008. <i>PLoS ONE</i> , 2010, 5, e13737.	2.5	66
17	A Preliminary Randomized Controlled Trial of a Nurse-Delivered Medication Adherence Intervention Among HIV-Positive Outpatients Initiating Antiretroviral Therapy in Beijing, China. <i>AIDS and Behavior</i> , 2011, 15, 919-929.	2.8	55
18	PrEP uptake preferences among men who have sex with men in China: results from a National Internet Survey. <i>Journal of the International AIDS Society</i> , 2019, 22, e25242.	3.0	55

#	ARTICLE	IF	CITATIONS
19	A fatal yellow fever virus infection in China: description and lessons. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-8.	6.4	52
20	Late Presentation into Care of HIV Disease and Its Associated Factors in Asia: Results of TAHOD. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 255-261.	1.2	48
21	Initiation of the National Free Antiretroviral Therapy Program in Rural China. , 0, , 96-124.		47
22	Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. <i>Aids</i> , 2010, 24, S62-S71.	2.1	46
23	The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	6.4	46
24	Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. <i>PLoS ONE</i> , 2016, 11, e0150512.	2.5	42
25	Two-step fitness selection for intra-host variations in SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110205.	6.2	42
26	Chinese Pediatric Highly Active Antiretroviral Therapy Observational Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 594-598.	2.1	37
27	Portable bacterial CRISPR transcriptional activation enables metabolic engineering in <i>Pseudomonas putida</i> . <i>Metabolic Engineering</i> , 2021, 66, 283-295.	7.0	36
28	Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. <i>International Journal of Epidemiology</i> , 2010, 39, ii56-ii64.	2.0	35
29	Mortality and Treatment Outcomes of China's National Pediatric Antiretroviral Therapy Program. <i>Clinical Infectious Diseases</i> , 2013, 56, 735-744.	5.6	34
30	Implementation of "TreatAll" at adult <sc>HIV</sc> care and treatment sites in the Global <sc>DEA</sc> Consortium: results from the Site Assessment Survey. <i>Journal of the International AIDS Society</i> , 2019, 22, e25331.	3.0	34
31	Hepatitis B and Hepatitis C Seroprevalence in Children Receiving Antiretroviral Therapy for Human Immunodeficiency Virus-1 Infection in China, 2005-2009. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 191-196.	2.1	33
32	Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, e150-e157.	2.1	33
33	Gender Difference in 2-Year Mortality and Immunological Response to ART in an HIV-Infected Chinese Population, 2006-2008. <i>PLoS ONE</i> , 2011, 6, e22707.	2.5	33
34	Interventions to improve the HIV continuum of care in China. <i>Current HIV/AIDS Reports</i> , 2019, 16, 448-457.	3.0	30
35	Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003-2010. <i>PLoS ONE</i> , 2012, 7, e39414.	2.5	30
36	"You Must Take the Medications for You and for Me": Family Caregivers Promoting HIV Medication Adherence in China. <i>AIDS Patient Care and STDs</i> , 2011, 25, 735-741.	2.5	28

#	ARTICLE	IF	CITATIONS
37	HIV testing and care systems focused on sexually transmitted HIV in China. <i>Sexually Transmitted Infections</i> , 2012, 88, 116-119.	2.4	28
38	Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. <i>Emerging Microbes and Infections</i> , 2020, 9, 2550-2561.	6.4	28
39	Genomic surveillance of COVID-19 cases in Beijing. <i>Nature Communications</i> , 2020, 11, 5503.	12.8	27
40	COVID-19 reinfection in the presence of neutralizing antibodies. <i>National Science Review</i> , 2021, 8, nwab006.	9.2	26
41	Excessive conversion and impaired thymic output contribute to disturbed regulatory T-cell homeostasis in AIDS patients with low CD4 cell counts. <i>Aids</i> , 2013, 27, 1059-1069.	2.1	25
42	Phylogenomic analysis unravels evolution of yellow fever virus within hosts. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006738.	2.4	25
43	Progress of the National Pediatric Free Antiretroviral Therapy program in China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 1182-1188.	1.2	23
44	Drug Resistance Profiles Among HIV-1-Infected Children Experiencing Delayed Switch and 12-Month Efficacy After Using Second-Line Antiretroviral Therapy: An Observational Cohort Study in Rural China. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 47-53.	2.1	23
45	Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China. <i>BMC Infectious Diseases</i> , 2016, 16, 82.	2.9	22
46	Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study. <i>Aids</i> , 2020, 34, 609-619.	2.1	22
47	Gender Differences in Outcomes of Antiretroviral Treatment Among HIV-Infected Patients in China: A Retrospective Cohort Study, 2010-2015. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 281-288.	2.1	21
48	PrEP in China: choices are ahead. <i>Lancet HIV</i> , 2020, 7, e155-e157.	4.5	21
49	Metabolism-dependent ferroptosis promotes mitochondrial dysfunction and inflammation in CD4+ T lymphocytes in HIV-infected immune non-responders. <i>EBioMedicine</i> , 2022, 86, 104382.	5.9	21
50	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. <i>PLoS ONE</i> , 2014, 9, e106525.	2.5	19
51	Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after highly active antiretroviral therapy (HAART) in China: a retrospective study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1127-1135.	1.2	18
52	Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. <i>PLoS ONE</i> , 2016, 11, e0161562.	2.5	18
53	The Diagnosis and Treatment of HIV-Infected Children in China. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 429-434.	2.1	17
54	The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. <i>Journal of the International AIDS Society</i> , 2019, 22, e25228.	3.0	16

#	ARTICLE	IF	CITATIONS
55	A Clinical Trial of Isradipine: What Went Wrong?. <i>Annals of Internal Medicine</i> , 2020, 172, 625-626.	10.0	16
56	Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 239-243.	2.1	16
57	The Prevalence of HIV-1 Drug Resistance among Antiretroviral Treatment Naïve Individuals in Mainland China: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e110652.	2.5	15
58	Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database. <i>AIDS Patient Care and STDs</i> , 2015, 29, 229-231.	2.5	15
59	Comparison of the Effectiveness of Single-Component and Multicomponent Interventions for Reducing Radiation Doses in Patients Undergoing Computed Tomography. <i>JAMA Internal Medicine</i> , 2020, 180, 666.	5.0	15
60	The Chinese Life-Steps Program: A Cultural Adaptation of a Cognitive-Behavioral Intervention to Enhance HIV Medication Adherence. <i>Cognitive and Behavioral Practice</i> , 2013, 20, 202-212.	1.8	13
61	Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. <i>Pharmacotherapy</i> , 2017, 37, 1073-1080.	2.6	13
62	Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. <i>Medical Science Monitor</i> , 2020, 26, e925974.	1.1	13
63	Some patient-related factors associated with late access to ART in China's free ART program. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1226-1235.	1.2	12
64	Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv158.	0.9	12
65	Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHO�. <i>Tropical Medicine and International Health</i> , 2016, 21, 662-674.	2.0	11
66	Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study. <i>Drug and Alcohol Dependence</i> , 2017, 170, 189-197.	3.2	11
67	Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1209-1216.	1.9	11
68	HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy. <i>International Journal of Infectious Diseases</i> , 2020, 91, 210-217.	3.3	11
69	Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 4529-4537.	2.7	11
70	Monitoring HIV Drug Resistance Using Early Warning Indicators in China: Results From a Pilot Survey Conducted in 2008. <i>Clinical Infectious Diseases</i> , 2012, 54, S300-S302.	5.6	10
71	Predictors of accessing antiretroviral therapy among HIV-positive drug users in China's national Methadone Maintenance Treatment Programme. <i>Addiction</i> , 2015, 110, 40-50.	4.8	10
72	Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1560-1566.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 195-203.	0.8	10
74	Knowledge and perceptions of sexual and reproductive health and HIV among perinatally HIV-infected adolescents in rural China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1137-1142.	1.2	9
75	Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 308-315.	2.1	9
76	First Case of Coronavirus Disease 2019 in Childhood Leukemia in China. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e142-e145.	2.0	9
77	Growth of HIV-Infected Children in the Early Stage of Antiretroviral Treatment: A Retrospective Cohort Study in China. <i>AIDS Patient Care and STDs</i> , 2016, 30, 365-370.	2.5	8
78	Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. <i>Journal of the International AIDS Society</i> , 2019, 22, e25264.	3.0	8
79	Specific dynamic variations in the peripheral blood lymphocyte subsets in COVID-19 and severe influenza A patients: a retrospective observational study. <i>BMC Infectious Diseases</i> , 2020, 20, 910.	2.9	8
80	Mitochondrial DNA mutations accumulated in HIV-1-infected children who have an excellent virological response when exposed to long-term antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3114-3121.	3.1	7
81	The Yield and Consistency of the Detection of SARS-CoV-2 in Multiple Respiratory Specimens. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa379.	0.9	7
82	Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severity. <i>Science China Life Sciences</i> , 2022, 65, 223-226.	5.0	7
83	Longitudinal analysis of new-onset non-AIDS-defining diseases among people living with HIV: A real-world observational study. <i>HIV Medicine</i> , 2022, 23, 32-41.	2.2	7
84	A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China. <i>Scientific Reports</i> , 2021, 11, 24353.	3.4	7
85	Efficacy and safety of abinavirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 36, 100769.	2.9	7
86	Unsafe Sex and STI Prevalence Among HIV-Infected Adults in Guangzhou, China: Opportunities to Deamplify Sexual HIV Transmission. <i>AIDS and Behavior</i> , 2013, 17, 1137-1143.	2.8	6
87	Progress and challenges in China's free ART programme. <i>Lancet HIV</i> , 2019, 6, e8-e9.	4.5	6
88	Specific Redistribution of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Respiratory System and Intestinal Tract. <i>Clinical Infectious Diseases</i> , 2021, 73, e2814-e2817.	5.6	6
89	Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. <i>HIV Medicine</i> , 2022, 23, 274-286.	2.2	6
90	Comparing Outcomes of HIV-Infected Chinese Adults on Antiretroviral Therapy by CD4 Count at Treatment Initiation: A Nationwide Retrospective Observational Cohort Study, 2012-2014. <i>AIDS Patient Care and STDs</i> , 2017, 31, 413-420.	2.5	5

#	ARTICLE	IF	CITATIONS
91	Two types of poor immunological responder showing distinct responses to long-term HAART. <i>International Journal of Infectious Diseases</i> , 2019, 86, 178-187.	3.3	5
92	Validation of the D:A:D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 489-497.	2.1	5
93	Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3763-3770.	2.7	5
94	Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1119-1124.	3.1	5
95	Recent key advances in human immunodeficiency virus medicine and implications for China. <i>AIDS Research and Therapy</i> , 2010, 7, 12.	1.8	4
96	Expansion of HIV care and treatment in Yunnan Province, China: Treatment outcomes with scale up of combination antiretroviral therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 633-641.	1.2	4
97	Brief Report: Malignancies in Adults Living With HIV in Asia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 301-307.	2.1	4
98	The stage-specific impairment of granulopoiesis in people living with HIV/AIDS (PLWHA) with neutropenia. <i>Journal of Leukocyte Biology</i> , 2020, 107, 635-647.	3.2	4
99	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25736.	3.0	4
100	Factors Associated with Survival Among Adults with HIV-Associated TB in Guangxi, China: A Retrospective Cohort Study. <i>Future Virology</i> , 2012, 7, 933-942.	1.7	3
101	Identification of a Novel HIV Type 1 CRF01_AE/B $\epsilon$ /C Recombinant Isolate in Sichuan, China. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 621-628.	1.2	3
102	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the <sc>TREAT</sc> Asia <sc>HIV</sc> Observational Database (<sc>TAHOD</sc>). <i>Journal of the International AIDS Society</i> , 2017, 20, e25016.	3.0	3
103	Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance. <i>Journal of Infectious Diseases</i> , 2017, 216, S816-S819.	3.9	3
104	Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 360-368.	2.1	3
105	Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	3
106	Near Full-Length Genome Identification of a Novel HIV-1 Unique (B/C) Recombinant Isolate in Sichuan, China. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1229-1233.	1.2	2
107	Phylogenomic tracing of asymptomatic transmission in a COVID-19 outbreak. <i>Innovation(China)</i> , 2021, 2, 100099.	7.9	2
108	Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. <i>Antiviral Therapy</i> , 2021, 25, 377-387.	0.9	2



#	ARTICLE	IF	CITATIONS
109	Strategy to Achieve Full Coverage in the National Free Antiretroviral Therapy Program. , 2020, , 271-289.		2
110	Seroprevalence of HBV and HCV Among HIV-Infected Adults in China According to Route of HIV Infection: High Rate of HBV and HCV Exposure. Future Virology, 2012, 7, 1015-1020.	1.7	1
111	Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy. Science China Life Sciences, 2021, 64, 152-161.	5.0	1
112	Reply to Aquino-Jarquín. Clinical Infectious Diseases, 2021, 72, 1490-1491.	5.6	1
113	Patterns and prognosis of holding regimens for people living with HIV in Asian countries. PLoS ONE, 2022, 17, e0264157.	2.5	1
114	A Concentration Method for HIV Drug Resistance Testing in Low-Level Viremia Samples. BioMed Research International, 2022, 2022, 1-6.	1.9	1
115	1569The effects of frequency of CD4 monitoring on clinical endpoints in clinically stable HIV-infected patients with viral suppression. Open Forum Infectious Diseases, 2014, 1, S418-S418.	0.9	0
116	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, 27.	1.8	0
117	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality. Open Forum Infectious Diseases, 2017, 4, S59-S59.	0.9	0
118	The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries. Open Forum Infectious Diseases, 2017, 4, S432-S432.	0.9	0
119	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 436-443.	2.1	0
120	The prevalence of HDV among HBsAg-positive populations with and without HIV-1 in China. International Journal of Infectious Diseases, 2024, 140, 70-77.	3.3	0
121	Long-term effect of antiretroviral therapy on mortality among HIV-positive children and adolescents in China. Heliyon, 2024, 10, e27961.	3.2	0